Biotheryx, Inc. revealed that their Investigational New Drug application for BTX-9341, an innovative bifunctional degrader targeting cyclin-dependent kinase 4/6 (CDK4/6).
Positive Phase 2 Results for XyloCor Therapeutics’ Main Candidate XC001 Announced at SCAI 2024 and in the Journal Circulation: Cardiovascular Interventions.
Remix Therapeutics has started dosing the first participants in a pair of Phase 1 studies. These trials are testing REM-422 in treating Adenoid Cystic Carcinoma (ACC) and Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS).
Alpha-9 Oncology reports initial dosing of the first participant in a phase 1 trial for A9-3202, targeting locally advanced or metastatic melanoma patients.
EyeDNA Therapeutics Reveals Encouraging Two-Year Results at ARVO for its Phase 1/2 Study on HORA-PDE6b Genetic Treatment in Retinitis Pigmentosa Patients with Dual Mutations in PDE6b.
Adcentrx Therapeutics has received IND approval from China's NMPA for ADRX-0706, a new Nectin-4 antibody-drug conjugate designed to treat advanced solid tumors.